Jefferies analyst Brian Abrahams saying Biogen's (NASDAQ: BIIB) aducanumab appears to be further de-risked based tidbit tucked away at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE